Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Thorsø Larsen A"'
Autor:
Khaled Elhady Mohamed, Anna Thorsø Larsen, Simone Melander, Frederik Andersen, Ellen Barendorff Kerrn, Morten Asser Karsdal, Kim Henriksen
Publikováno v:
Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-11 (2024)
Abstract Background Despite the extensive research to provide a disease-modifying osteoarthritis drug (DMOAD), there is still no approved DMOAD. Dual amylin and calcitonin receptor agonists (DACRA) can provide metabolic benefits along with antinocice
Externí odkaz:
https://doaj.org/article/3573830610a348da9a886335d22b38fc
Publikováno v:
In European Journal of Pharmacology 5 September 2023 954
Autor:
Anna Thorsø Larsen, Simone A. Melander, Nina Sonne, Emma Bredtoft, Mays Al-Rubai, Morten A. Karsdal, Kim Henriksen
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 164, Iss , Pp 114969- (2023)
Dual amylin and calcitonin receptor agonists (DACRAs) are known to induce significant weight loss as well as improve glucose tolerance, glucose control, and insulin action in rats. However, to what extent DACRAs affect insulin sensitivity beyond that
Externí odkaz:
https://doaj.org/article/9fd5996a18724e019ef328a1522bed34
Publikováno v:
BMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Weight loss therapy is becoming more and more important, and two classes of molecules, namely amylin receptor and GLP-1 receptor agonists, have shown promise in this regard. Interestingly, these molecules have several overlapping
Externí odkaz:
https://doaj.org/article/c71fe40f440c43deb8dae3b003dd4193
Publikováno v:
Biomedicines, Vol 10, Iss 10, p 2365 (2022)
Background: Dual Amylin and Calcitonin Receptor Agonists (DACRAs) are treatment candidates for obesity and type 2 diabetes. Recently, a once-weekly DACRA (KBP-A) showed promise, potentially due to its different exposure profile compared to daily DACR
Externí odkaz:
https://doaj.org/article/6425aa391afa4888abc1d5be6ca5c1f1
Publikováno v:
BMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Endocrine Disorders
BMC Endocrine Disorders
Background Weight loss therapy is becoming more and more important, and two classes of molecules, namely amylin receptor and GLP-1 receptor agonists, have shown promise in this regard. Interestingly, these molecules have several overlapping pharmacol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c2adf23bbf84aa4d57fac2c77590782
https://doaj.org/article/c71fe40f440c43deb8dae3b003dd4193
https://doaj.org/article/c71fe40f440c43deb8dae3b003dd4193
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 374:74-83
Amylin treatment improves body weight and glucose control, although it is limited by a short action and need for high doses. Dual amylin and calcitonin receptor agonists (DACRAs) are dual amylin and calcitonin receptor agonists with beneficial effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::649b6476f50f13fbc96a8d506a871e8f
https://doi.org/10.1124/jpet.119.263392
https://doi.org/10.1124/jpet.119.263392
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 373:92-102
Pharmacological treatment with Dual Amylin and Calcitonin Receptor Agonists (DACRAs) cause a significant weight loss and improvement of glucose homeostasis. In this study, the maximally efficacious dose of the novel DACRA, KBP-066, was investigated.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e43cf0b496ca01331144b2a815204116
https://doi.org/10.1124/jpet.119.263723
https://doi.org/10.1124/jpet.119.263723
Autor:
Nina Sonne, Kim Henriksen, Kim Vietz Andreassen, Kristoffer Gehring, Morten A. Karsdal, Anna Thorsø Larsen
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 370:35-43
KBP-088 (KeyBiosciencePeptide 088) is a potent dual amylin and calcitonin receptor agonist (DACRA). DACRAs are known to elicit potent activity in terms of typical amylin-induced responses, such as reducing food intake and body weight. However, to wha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::760d25c3f9ed563b6ec47fdc28a0e712
https://doi.org/10.1124/jpet.119.257576
https://doi.org/10.1124/jpet.119.257576
Background: Weight loss therapy is becoming more and more important, and two classes of molecules, namely amylin receptor and GLP-1 receptor agonists, have shown promise in this regard. Interestingly, these molecules have several overlapping pharmaco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e5fe2f98c0ded20f11c3cb1be3ab519
https://doi.org/10.21203/rs.3.rs-39438/v2
https://doi.org/10.21203/rs.3.rs-39438/v2
